Traders Sell Pfizer Inc. (PFE) on Strength (PFE)
Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Monday. $58.68 million flowed into the stock on the tick-up and $116.65 million flowed out of the stock on the tick-down, for a money net flow of $57.97 million out of the stock. Of all equities tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.04 for the day and closed at $36.78
A number of research analysts have issued reports on the company. BMO Capital Markets reiterated a “buy” rating on shares of Pfizer in a research report on Thursday, April 28th. Sanford C. Bernstein set a $36.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, May 3rd. Independent Research GmbH set a $37.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Wednesday, May 4th. Goldman Sachs Group Inc. restated a “neutral” rating and issued a $35.00 price objective on shares of Pfizer in a report on Monday, April 18th. Finally, S&P Equity Research restated a “buy” rating on shares of Pfizer in a report on Tuesday, April 12th. Ten investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $38.19.
The firm has a market capitalization of $223.07 billion and a PE ratio of 30.15. The firm’s 50 day moving average is $35.47 and its 200 day moving average is $32.44.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.12. During the same quarter in the previous year, the business earned $0.51 EPS. The company had revenue of $13 billion for the quarter, compared to analysts’ expectations of $12 billion. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post $2.45 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Friday, August 5th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Wednesday, August 3rd. This represents a $1.20 annualized dividend and a dividend yield of 3.26%.
In related news, EVP Douglas M. Lankler sold 29,700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $33.69, for a total value of $1,000,593.00. Following the completion of the transaction, the executive vice president now directly owns 124,920 shares of the company’s stock, valued at approximately $4,208,554.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Anthony J. Maddaluna sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $33.75, for a total transaction of $302,062.50. Following the completion of the transaction, the executive vice president now directly owns 88,922 shares of the company’s stock, valued at $3,001,117.50. The disclosure for this sale can be found here.
Other hedge funds and institutional investors have added to or reduced their stakes in the company. Transamerica Financial Advisors Inc. increased its position in Pfizer by 6.0% in the fourth quarter. Transamerica Financial Advisors Inc. now owns 145,101 shares of the biopharmaceutical company’s stock valued at $4,684,000 after buying an additional 8,218 shares during the period. Sheets Smith Wealth Management increased its position in Pfizer by 1.3% in the fourth quarter. Sheets Smith Wealth Management now owns 33,001 shares of the biopharmaceutical company’s stock valued at $1,065,000 after buying an additional 436 shares during the period. Fort Pitt Capital Group LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $6,324,000. World Asset Management Inc increased its position in Pfizer by 4.7% in the fourth quarter. World Asset Management Inc now owns 643,965 shares of the biopharmaceutical company’s stock valued at $20,787,000 after buying an additional 29,078 shares during the period. Finally, First Merchants Corp increased its position in Pfizer by 8.2% in the fourth quarter. First Merchants Corp now owns 46,918 shares of the biopharmaceutical company’s stock valued at $1,514,000 after buying an additional 3,572 shares during the period.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.